Amit Maity has been named professor and chair of the Department of Radiation Oncology for the Spencer Fox Eccles School of Medicine at University of Utah.
Marshall Medical Center in Placerville, CA, and UC Davis Health have entered an affiliation for cancer services that allows Marshall patients access to the UC Davis Comprehensive Cancer Center through the UC Davis Health Cancer Care Network.
Danish Ahmad has joined Fox Chase Cancer Center as an assistant professor in the Department of Medicine for the Division of Pulmonary, Sleep and Critical Care Medicine. Ahmad began his tenure at Fox Chase on Nov. 8. 2021.
Researchers at Fox Chase Cancer Center have received a $497,000 multi-year grant from NCI to develop a way to evaluate novel drug therapies in patients with pancreatic cancer.
The National Comprehensive Cancer Network has published updates to the expert consensus recommendations on vaccination and pre-exposure prophylaxis of COVID-19 in people with cancer.
A three-drug combination could help patients with aggressive forms of blood cancer achieve longer cancer remission after undergoing allogeneic stem cell transplantation, according to preliminary clinical trial results presented by researchers at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James).
According to the results of the ZUMA-7 clinical trial, the CAR T-cell therapy Yescarta (axicabtagene ciloleucel) is significantly more effective than the current standard of care in treating people with large B-cell lymphoma who relapse after the first line of treatment.
In patients with untreated, advanced melanoma, the combination of immune checkpoint inhibitors relatlimab and Opdivo (nivolumab) doubled the progression-free survival benefit compared to Opdivo alone, with a manageable safety profile, according to results of the phase II/III RELATIVITY-047 clinical trial reported by The University of Texas MD Anderson Cancer Center.
Patients with melanoma who reported eating more fiber-rich foods when they began immunotherapy survived longer without cancer growth than patients with insufficient dietary fiber intake, according to research from The University of Texas MD Anderson Cancer Center.
FDA has cleared the Investigational New Drug application for P-MUC1C-ALLO1, an allogeneic CAR T-cell product candidate targeting multiple solid tumor indications. The product is sponsored by Poseida Therapeutics.
